Roche Navigation Menu Strona główna : Strona główna
  • Kontakt
  • Szukaj...
Roche
  • W górę
  • Start
  • Search
  • Close search

						
							

Searching

    • Start
    • Produkty
      Produkty Przegląd
      • Onkologia
      • Cotellic®▼+ Zelboraf®
      • Erivedge®
      • Gazyvaro
      • Herceptin®
      • Kadcyla
      • MabThera® SC
      • Perjeta®
      • Polivy®▼
      • Tecentriq®
      • Stwardnienie rozsiane
      • Ocrevus®▼
      • Hemofilia
      • Hemlibra®▼
      • Reumatologia
      • RoActemra - ChPL
      • Rdzeniowy zanik mięśni
      • Evrysdi
      • Okulistyka
      • Vabysmo®▼
      • Choroby zakaźne
      • Ronapreve▼
      • Tamiflu®
      • Pozostałe produkty A-Z
      • Mircera®
    • Obszary terapeutyczne
      Obszary terapeutyczne Przegląd
      • Rak Płuca
      • 7 minut z Ekspertem - Rak Płuca
      • Diagnostyka Raka Płuca
      • Okulistyka
      • Roche w okulistyce
      • Angiopoetyna
      • Stabilność naczyniowa
      • Eye on travel
      • Kontakt
      • Rak Wątrobowokomórkowy
      • Reumatoidalne zapalenie stawów
      • Profile pacjentów
      • Okiem Eksperta
      • Podcast
    • Materiały edukacyjne
      Materiały edukacyjne Przegląd
    • Informacja medyczna
      Informacja medyczna Przegląd
    • Bezpieczeństwo farmakoterapii
      Bezpieczeństwo farmakoterapii Przegląd
    • Profilowanie genomowe
      Profilowanie genomowe Przegląd
    • Lekarz Rezydent
      Lekarz Rezydent Przegląd
    • RDTL
      RDTL Przegląd
    • Start
    • Produkty
      • Onkologia
        • Cotellic®▼+ Zelboraf®
        • Erivedge®
        • Gazyvaro
        • Herceptin®
        • Kadcyla
        • MabThera® SC
        • Perjeta®
        • Polivy®▼
        • Tecentriq®
      • Stwardnienie rozsiane
        • Ocrevus®▼
      • Hemofilia
        • Hemlibra®▼
      • Reumatologia
        • RoActemra - ChPL
      • Rdzeniowy zanik mięśni
        • Evrysdi
      • Okulistyka
        • Vabysmo®▼
      • Choroby zakaźne
        • Ronapreve▼
        • Tamiflu®
      • Pozostałe produkty A-Z
        • Mircera®
    • Obszary terapeutyczne
      • Rak Płuca
        • 7 minut z Ekspertem - Rak Płuca
        • Diagnostyka Raka Płuca
      • Okulistyka
        • Roche w okulistyce
        • Angiopoetyna
        • Stabilność naczyniowa
        • Eye on travel
        • Kontakt
      • Rak Wątrobowokomórkowy
      • Reumatoidalne zapalenie stawów
        • Profile pacjentów
        • Okiem Eksperta
        • Podcast
    • Materiały edukacyjne
    • Informacja medyczna
    • Bezpieczeństwo farmakoterapii
    • Profilowanie genomowe
    • Lekarz Rezydent
    • RDTL
    • Kontakt
    Zamknij

    1 - of Wyniki wyszukiwania dla ""

    No results

    ronapreve
    • Ronapreve▼
    • Dosage
    • Safety
    • Clinical Trials
    • Resistance
    • Actual SmPC
    • Więcej
      • Dosage
      • Safety
      • Clinical Trials
      • Resistance
      • Actual SmPC

    Jesteś tutaj

    1. Produkty
    2. Choroby zakaźne
    3. Ronapreve▼
    4. Dosage

    Posology and method of administration

    Administration should be under conditions where management of severe hypersensitivity reactions, such as anaphylaxis, is possible. Individuals should be monitored after administration according to local medical practice.

     

    Posology

    Treatment

    The dosage in adult patients and in adolescent patients 12 years of age and older weighing at least 40 kg is 600 mg of casirivimab and 600 mg of imdevimab administered as a single intravenous infusion or by subcutaneous injection (see Table 1). See sections 4.4 and 5.1.

    Casirivimab with imdevimab should be given within 7 days of the onset of symptoms of COVID-19.

     

    Prevention

    Post-exposure prophylaxis

    The dosage in adult patients and in adolescent patients 12 years of age and older weighing at least 40 kg is 600 mg of casirivimab and 600 mg of imdevimab administered as a single intravenous infusion or by subcutaneous injection (see Tables 1 and 2).

    Casirivimab with imdevimab should be given as soon as possible after contact with a case of COVID-19.

     

    Pre-exposure prophylaxis

    The initial dose in adult patients and in adolescent patients 12 years of age and older weighing at least 40 kg is 600 mg of casirivimab and 600 mg of imdevimab administered as a single intravenous infusion or by subcutaneous injection (see Tables 1 and 2). Subsequent doses of 300 mg of casirivimab and 300 mg of imdevimab administered as a single intravenous infusion or by subcutaneous injection may be given every 4 weeks until prophylaxis is no longer required. There are no data on repeat dosing beyond 24 weeks (6 doses).

     

    Missed dose

    In case of repeated dosing for pre-exposure prophylaxis, if a dose of Ronapreve is missed it should be administered as soon as possible. Thereafter, the schedule of administration should be adjusted to maintain the appropriate interval between doses.

     

    Special populations

    • Elderly - No dosage adjustment is required (see section 5.2 SmPC).
    • Renal impairment - No dosage adjustment is required (see section 5.2 SmPC). 
    • Hepatic impairment - No dosage adjustment is required (see section 5.2 SmPC).
    • Paediatric population - The safety and efficacy of casirivimab and imdevimab in children < 12 years of age has not yet been established. No data are available.

     

    Preparation

    Preparation of Ronapreve for intravenous infusion

    Ronapreve should be prepared by a healthcare professional using aseptic technique:

    1. Remove the casirivimab and imdevimab vials from refrigerated storage and allow to equilibrate to room temperature for approximately 20 minutes before preparation.
    2. -  Do not expose to direct heat.

      -  Do not shake the vials.

    3. Inspect casirivimab and imdevimab vials visually for particulate matter and discolouration prior to administration. Should either be observed, the vial must be discarded and replaced with a new vial.
    4. -  The solution for each vial should be clear to slightly opalescent, colourless to pale yellow.

    5. Obtain a prefilled intravenous infusion bag [made from polyvinyl chloride (PVC) or polyolefin (PO)] containing either 50 mL, 100 mL, 150 mL, or 250 mL of 0.9% sodium chloride injection or 5% dextrose injection.
    6. Using a sterile syringe and needle, withdraw the appropriate volume of casirivimab and imdevimab from each respective vial and inject into a prefilled infusion bag containing 0.9% sodium chloride injection or 5% dextrose injection (see section 4.2, Table 1).
    7. Gently mix infusion bag by inversion. Do not shake.
    8. Ronapreve is preservative‑free and therefore, the diluted infusion solution should be administered immediately.

    Administration of Ronapreve by intravenous infusion

    • Gather the recommended materials for infusion:
      • Polyvinyl chloride (PVC), polyethylene (PE)‑lined PVC, or polyurethane (PU) infusion set
      • In-line or add-on 0.2 μm to 5 μm polyethersulfone, polysulfone, or polyamide filter for intravenous administration.
    • Attach the infusion set to the intravenous bag.
    • Prime the infusion set.
    • Administer the entire infusion solution in the bag via pump or gravity through an intravenous line containing a sterile, in-line or add-on 0.2 μm to 5 μm polyethersulfone, polysulfone, or polyamide filter for intravenous administration.
    • The prepared infusion solution should not be administered simultaneously with any other medicinal product. The compatibility of casirivimab and imdevimab injection with intravenous solutions and medicinal products other than 0.9% sodium chloride injection or 5% dextrose injection is not known.
    • After infusion is complete, flush the tubing with 0.9% sodium chloride injection or 5% dextrose injection to ensure delivery of the required dose.
    •  Individuals should be monitored post intravenous infusion according to local medical practice.

    Preparation of Ronapreve for subcutaneous injection

    Remove the casirivimab and imdevimab vial(s) from refrigerated storage and allow to equilibrate to room temperature for approximately 20 minutes before preparation.

    Do not expose to direct heat.

    Do not shake the vials.

     

    Inspect casirivimab and imdevimab vial(s) visually for particulate matter and discolouration prior to administration. Should either be observed, the vial must be discarded and replaced with a new vial. The solution for each vial should be clear to slightly opalescent, colourless to pale yellow.

    1. Ronapreve should be prepared using the appropriate number of syringes (see section 4.2, Table 2). Obtain 3 mL or 5 mL polypropylene syringes with luer connection and 21-gauge transfer needles.
    2. Using a sterile needle and syringe, withdraw the appropriate volume of casirivimab and imdevimab from each respective vial into each syringe (see section 4.2, Table 2) for a total of 4 syringes for the 1 200 mg combined total dose and a total of 2 syringes for the 600 mg combined total dose. Store any remaining product as directed in Section 6.3.
    3. Replace the 21-gauge transfer needle with a 25-gauge or 27-gauge needle for subcutaneous injection.
    4. This product is preservative-free and therefore, the prepared syringes should be administered immediately. If immediate administration is not possible, store the prepared casirivimab and imdevimab syringes at 2 ºC to 8 ºC for no more than 72 hours and at room temperature up to 25 ºC for no more than 24 hours. If refrigerated, allow the syringes to equilibrate to room temperature for approximately 10-15 minutes prior to administration.

    Administration of Ronapreve by subcutaneous injection

    • For the administration of Ronapreve 1 200 mg dose (600 mg of casirivimab and 600 mg of imdevimab), gather 4 syringes (see section 4.2, Table 2) and prepare for subcutaneous injections.
    • For the administration of Ronapreve 600 mg dose (300 mg of casirivimab and 300 mg of imdevimab), gather 2 syringes (see section 4.2, Table 2) and prepare for subcutaneous injections.
    • Due to the volume, administer the subcutaneous injections consecutively, at separate body sites (into upper thighs, upper outer arms, or abdomen, avoiding 5 cm around the navel and the waistline).

    Method of administration

    Ronapreve is for intravenous or subcutaneous use only.

    Table 1:  Recommended dilution instructions for Ronapreve (casirivimab and imdevimab) for intravenous infusion

    Indication
    Ronapreve Dose
    Total Volume for 1 Dose
    Volume to be withdrawn from each respective vial and injected into a single prefilled 0.9% sodium chloride or 5% dextrose infusion bag of 50-250 mL for co-administration

    Treatment,  Post-exposure prophylaxis (single dose), Pre-exposure prophylaxis (initial dose)

    600 mg casirivimab and 600 mg imdevimab

    10 mL

    5 mL from one 1 332 mg multidose vial of casirivimab

    5 mL from one 1 332 mg multidose vial of imdevimab

     

    Pre-exposure prophylaxis (repeat dose)

    300 mg casirivimab and 300 mg imdevimab

    5 mL

    2.5 mL from one 1 332 mg multidose vial of casirivimab

    2.5 mL from one 1 332 mg multidose vial of imdevimab

    The infusion should be administered over 20-30 minutes. The rate of infusion may be slowed, interrupted or discontinued if the patient develops any signs of infusion-associated events or other adverse reactions. 

     

    Table 2: Preparation of Ronapreve (casirivimab and imdevimab) for subcutaneous injection

    Indication
    Ronapreve Dose
    Total Volume for 1 Dose
    Volume to be withdrawn from each respective vial to prepare 4 syringes

    Treatment, Post-exposure prophylaxis (single dose), Pre-exposure prophylaxis (initial dose)

    600 mg casirivimab and 600 mg imdevimab

    10 mL

    2.5 mL (2x) from one 1 332 mg multidose vial of casirivimab

    2.5 mL (2x) from one 1 332 mg multidose vial of imdevimab

     

    Indication
    Ronapreve Dose
    Total Volume for 1 Dose
    Volume to be withdrawn from each respective vial to prepare 2 syringes

    Pre-exposure prophylaxis (repeat dose)

    300 mg casirivimab and 300 mg imdevimab

    5 mL

    2.5 mL from one 1 332 mg multidose vial of casirivimab

    2.5 mL from one 1 332 mg multidose vial of imdevimab

    M-PL-00002072

     

    References:

    • Summary of Product Characteristic https://www.roche.pl/content/dam/rochexx/roche-pl/roche_poland_rwd/pl_PL/documents/SmPC/Ronapreve_1332.pdf

    ▼The medicinal product is additionally monitored. This will allow you to quickly identify new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

    Reports of adverse reactions should be submitted to: Department of Monitoring Undesirable Effects of Medicinal Products, Office for Registration of Medicinal Products, Medical Devices and Biocidal Products, Al. Jerozolimskie 181 C, 02-222 Warsaw, phone: + 48 22 49 21 301; fax: + 48 22 49 21 309; website: https://smz.ezdrowie.gov.pl or Roche Polska Sp. z o.o., ul. Domaniewska 28, 02-672 Warsaw, tel. +48 22 345 18 88, fax +48 22 345 18 74 or using the application form available at www.roche.pl/portal/pl/zglaszanie_dzialan_niepozadanych.

     

    Uwaga

    Oświadczam, że jestem lekarzem medycyny, farmaceutą lub osobą prowadzącą obrót produktami leczniczymi. Podmiotem odpowiedzialnym za treści zamieszczone na portalu internetowym dlalekarzy.roche.pl jest spółka Roche Polska Sp. z o.o. z siedzibą w Warszawie, ul. Domaniewska 28, 02-672, KRS: 0000118292. UWAGA! Portal ten zawiera treści będące reklamą produktów leczniczych wydawanych jedynie na podstawie recepty w rozumieniu ustawy z dnia 6 września 2001 roku Prawo farmaceutyczne (t. jedn.: Dz.U. 2008, Nr 45, poz 271 z późn. zm.) („Prawo farmaceutyczne”). Zasoby portalu internetowego dlalekarzy.roche.pl są dostępne jedynie dla osób uprawnionych do wystawiania recept lub osób prowadzących obrót produktami leczniczymi. Jeśli nie spełniasz wymienionych warunków, kliknij przycisk NIE. (t.jedn.: Dz.U. 2017 poz. 2211 ze zm.).

    Tak Nie
    • © 2023
    • 19.01.2023
    • Polityka prywatności
    • Nota prawna
    • Cookie settings

    Podmiotem odpowiedzialnym za treści zamieszczone na portalu internetowym dlalekarzy.roche.pl jest spółka Roche Polska Sp. z o.o. z siedzibą w Warszawie, ul. Domaniewska 28, 02-672, KRS: 0000118292. Informacje publikowane na Portalu stanowią reklamę produktów leczniczych w rozumieniu ustawy z dnia 6 września 2001 r. Prawo farmaceutyczne (t. jedn.: Dz. U. 2021 poz. 974). Zasoby portalu internetowego dlalekarzy.roche.pl dostępne są wyłacznie dla osób uprawnionych do wystawiania recept lub osób prowadzących obrót produktami leczniczymi.